CVRx, Inc. (NASDAQ:CVRX), a medical device company listed on the Nasdaq Global Select Market, filed a current report on September 21, 2026, disclosing the appointment of John Landry as Chief Financial Officer, effective following a transition period beginning October 12, 2026.
Key Highlights
- New CFO appointed: CVRx's Board of Directors appointed John Landry as Chief Financial Officer on September 21, 2026.
- Employment start date: Mr. Landry's employment commences October 12, 2026, with full CFO responsibilities assumed the day after CVRx files its quarterly report for the period ending September 30, 2026.
- Annual base salary: Mr. Landry's initial annual base salary was set at $500,000, with a target cash incentive award of 50% of base salary, pro-rated for fiscal 2026.
- Equity award: Initial equity grants represent 0.80% of the base total common shares outstanding as of his employment commencement date, composed 75% of stock options and 25% of restricted stock units, granted under the Nasdaq inducement grant exemption.
- Predecessor's resignation: Outgoing CFO Jared Oasheim gave notice of his intention to resign on June 8, 2026, and will remain until his successor assumes full responsibilities.
- Prior CFO experience: Mr. Landry has served as CFO of Nyxoah SA since November 2024 and previously held CFO roles at Vapotherm Inc. from August 2012 to October 2024.
CVRx CFO Transition: Background, Compensation, and Timing
According to the filing, CVRx, Inc. is an emerging growth company incorporated in Delaware, headquartered at 9201 West Broadway Avenue, Suite 650, Minneapolis, MN 55445. The company's common stock, par value $0.01 per share, trades under the symbol CVRX on the Nasdaq Global Select Market. The Board's decision to appoint a new CFO follows the previously disclosed resignation notice of Jared Oasheim, who will remain in the role until the transition is complete.
The filing describes Mr. Landry, age 54, as currently serving as CFO of Nyxoah SA, which the filing characterizes as "a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea." Before that, he served in CFO and treasurer roles at Vapotherm Inc., described in the filing as "a developer and manufacturer of advanced respiratory technology," from August 2012 to October 2024. He also previously held a director-level role at Medtronic following its August 2011 acquisition of Salient Surgical Technologies, where he held positions from 2004 to 2011. He holds a B.S. in Accountancy from Bentley College and is a certified public accountant (inactive).
The Compensation Committee approved an offer letter dated September 16, 2026. In addition to base salary and the equity awards, the compensation package includes payment of a forfeited pro-rated bonus from his current employer, subject to repayment if Mr. Landry resigns or is terminated for cause before the first anniversary of his hire date, and reimbursement of travel expenses from his residence, according to the filing. Mr. Landry will also receive the company's standard form of severance agreement for executive officers.
What Was Disclosed
CVRx disclosed the appointment of John Landry as CFO, his compensation terms, his professional background in medical technology finance, and the planned transition from outgoing CFO Jared Oasheim, with full responsibilities commencing after the September 30, 2026 quarterly filing.



Please wait processing your request...